Navigation Links
Lexicon Announces Top-Line Phase 2a Data for LX2931 in Patients with Rheumatoid Arthritis
Date:12/14/2010

diseases.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.

In addition to LX2931, Lexicon has three other drug candidates progressing through Phase 2 clinical trials:  LX4211, an orally-delivered, once-daily, dual inhibitor of sodium glucose transporter 1 (SGLT1) and SGLT2 for type 2 diabetes; LX1031, a locally-acting serotonin synthesis inhibitor for irritable bowel syndrome; and LX1032, a peripherally-available serotonin synthesis inhibitor for carcinoid syndrome.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to the characterization of the safety profile of LX2931 observed in the Phase 2 clinical trial as favorable, the characterization of the results of the Phase 2 clinical trial of LX2931 as demonstrating a preliminary signal of efficacy and supporting further study as a potential treatment for rheumatoid arthritis, the mechanism of action of LX2931, and the potential therapeutic and commercial potential of LX2931 generally. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other m
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014  Luminex Corporation (Nasdaq: LMNX ... for the fourth quarter of 2013 on Monday, February ... scheduled for release after the close of trading. ... will hold a conference call to discuss the operating ... twelve months ended December 31, 2013 on February 3, ...
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ... maintain the anatomical reduction (spacing) of the scaphoid and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, ... development of disease modifying therapeutics for Alzheimer,s disease ... relocation of its corporate headquarters to ... 2014 and expanded lease agreement for additional laboratory ... Oligomerix, which is focused on the development of ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey ... is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the ... , , ... , , ...
... Calif. , July 22 SRI International and the ... Collaborative (the Multidisciplinary Initiative for Surgical Technology Research Advanced Laboratory), in ... $1M grant by the Food and Drug Administration (FDA) ... care. , , ...
Cached Medicine Technology:Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 2Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 2SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 3SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 4SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 5SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 6SRI International and Stanford University School of Medicine's MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices 7
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... The Coalition for,Pulmonary Fibrosis today announced 2007 National ... weekend in Washington, D.C., a,congressional reception that includes a ... with the National Institutes of Health. More,than 40 Idiopathic ... the Hill next week to meet with Members of ...
... As we age, our brains slowly shrink in volume ... lobes, the seat of executive functioning. Executive functions include ... aging population, an inability to inhibit unwanted thoughts and ... awry. , In a study appearing in the ...
... rather than womens newfound economic independence can explain why ... and why the trend may only be temporary, says ... women acquired significant control over their own fertility, and ... burden of raising children, says Lonnie Aarssen, a Biology ...
... 21 September 2007: New guidelines on the diagnosis and ... the Archives of Disease in Childhood, are set to ... the most common food allergy in children.1 The Guidelines ... Allergy recommend only extensively hydrolysed (eHF) and amino acid-based ...
... may take decades to reverse the health threats, experts say ... and ,90s, Americans tried to control their weight by watching ... paid little mind to total calories and physical activity. And ... , "It was just an end run around the issue ...
... RESTON, Va. -- Attention scientific researchers: SNM invites ... especially those involving non-radioactive molecular imaging techniques and ... June 1418, 2008, in New Orleans, La. SNM, ... nuclear medicine professionals, will showcase these studies in ...
Cached Medicine News:Health News:CPF Announces National IPF Awareness Week Activities 2Health News:CPF Announces National IPF Awareness Week Activities 3Health News:Brain atrophy in elderly leads to unintended racism, depression and problem gambling 2Health News:Is there really a 'mommy' gene in women? 2Health News:New guidelines set to improve standard of cows' milk allergy care 2Health News:New guidelines set to improve standard of cows' milk allergy care 3Health News:Childhood Obesity Epidemic a Long-Term Challenge 2Health News:Childhood Obesity Epidemic a Long-Term Challenge 3Health News:SNM seeks novel approaches to molecular imaging to showcase at annual meeting 2
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
For the quantitative in vitro determination of IgG in serum and plasma. This product is suitable for use on the Aeroset...
Latex-enhanced immunoturbidimetric assay for the quantitative in vitro determination of C-reactive protein in serum and plasma...
Medicine Products: